Avandia Survives Scrutiny From FDA Panel
After a contentious day of hearings, a panel of U.S. Food and Drug Administration advisers has overwhelmingly voted to keep Avandia on the market despite data that suggests the controversial diabetes...To view the full article, register now.
Already a subscriber? Click here to view full article